[ad_1]
The Ebola vaccine is used against viral haemorrhagic fever due to Ebola virus disease. This disease was initially transmitted from animals to humans, then pbaded from man to man. Ebola virus disease is considered a life-threatening disease and the main means of transferring this disease is direct contact with the body fluids of infected people / animals.
The intensification of research and development of Ebola vaccines around the world is one of the major factors driving the growth of the global market for Ebola vaccines. According to data published by The Lancet – a medical journal, Newlink Genetics and Merck and Company developed in December 2016 the V920 vaccine (rVSV-ZEBOV), which has been shown to be effective against the Ebola virus during the past decade. phase III clinical trial.
However, there is no medicine available to cure this disease, only a few preventive methods are followed to help the patient improve his health. In addition, various Ebola vaccines are under development and are expected to be commercialized shortly.
The growing prevalence of Ebola worldwide is a major factor in the growth of the global Ebola vaccine market. According to data published by the World Health Organization (WHO) in January 2018, the death rate from the Ebola virus is around 50%.
The global market for Ebola vaccine has been segmented based on the virus strain and the region. Based on the viral strain, the global Ebola vaccine market has been segmented into Chimpanzee type 3-Zaire type 3-Zaire Ebola virus, recombinant vesicular stomatitis virus – Zaire Ebola virus and Adenovirus 26 virus. from Zaire.
For an example copy of the report, visit @ https://marketresearch.biz/report/ebola-vaccine-market/request-sample/
Regional segmentation includes North America, Europe, Latin America, Asia-Pacific, the Middle East and Africa. North America represents a significant market share and is expected to maintain its dominant position over the forecast period due to the presence of major players and the high rate of vaccine development in the region. The Asia-Pacific region is expected to grow rapidly during the forecast period. Countries such as India and China are expected to support market growth, due to the government's growing willingness to raise public awareness of the Ebola vaccine.
Key players in the global Ebola vaccine market include Sarepta Therapeutics Inc., Mapp Biopharmaceutical, Inc., Regeneron Pharmaceuticals, Inc., Merck & Company, Inc., GlaxoSmithKline plc, Novavax Inc. and GeoVax Labs Inc. .
Source link
